AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30980399 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydroxychloroquine and sorafenib
Number of subjects: 0
Study 28193219 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Advice
Number of subjects: 1951
Study 28193219 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 1951
Study 25479969 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert PBA
Number of subjects: 8
Study 25479969 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt PBA
Number of subjects: 8
Study 25479969 — intervention group
Group type: COMPARATOR
Intervention: Control (no armour)
Number of subjects: 8
Study 23256574 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch 1 - 3 mg/24 h
Number of subjects: 198
Study 22091993 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal Natural Orifice Transluminal Endoscopic Surgery (NOTES)
Number of subjects: 12
Study 22091993 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy
Number of subjects: 12
Study 18438227 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exercise energy supplement (combination of branched chain amino acids, creatine, taurine, caffeine, and glucuronolactone)
Number of subjects: 8
Study 18438227 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exercise energy supplement
Number of subjects: 8
Study 18438227 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 8
Study 18438227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 17067583 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical removal of the pronucleus located at the farthest position to the second polar body (intervention group)
Number of subjects: 114
Study 17067583 — intervention group
Group type: COMPARATOR
Intervention: Triploid control group (control group)
Number of subjects: 114
Study 17067583 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated embryos (intervention group)
Number of subjects: 114
Study 12895612 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined procedure (Group A)
Number of subjects: 67
Study 12895612 — intervention group
Group type: COMPARATOR
Intervention: Valve procedure alone (Group B)
Number of subjects: 67
Study 12895612 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study 12907538 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential i.v./po moxifloxacin monotherapy (400 mg qd)
Number of subjects: 0
Study 12907538 — intervention group
Group type: COMPARATOR
Intervention: i.v./po co-amoxiclav (1.2 g i.v./625 mg po tid) with or without clarithromycin (500 mg bid)
Number of subjects: 0
Study 10200750 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced acute-phase treatment for depression
Number of subjects: 156
Study 10200750 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment for depression
Number of subjects: 156
Study 7634752 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of insulin-like growth factor I (30 micrograms h-1 kg-1) and insulin (0.23 nmol h-1 kg-1)
Number of subjects: 3
Study 7634752 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of insulin-like growth factor I (5 micrograms h-1 kg-1) and insulin (0.04 nmol h-1 kg-1)
Number of subjects: 3
Study 7634752 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 3
Study 7634752 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 3
Study 2694482 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine alone (250 mg/week)
Number of subjects: 175
Study 2694482 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine, sulfadoxine (500 mg/week), and pyrimethamine (25 mg/week) (MSP)
Number of subjects: 175
Study 2694482 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 175
Study 2694482 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine alone
Number of subjects: 175
Study 793186 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (2 X 50 mg daily)
Number of subjects: 46
Study 793186 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone (2 X 300 mg daily)
Number of subjects: 46
Study 31132159 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month recall period survey
Number of subjects: 2425
Study 31132159 — intervention group
Group type: COMPARATOR
Intervention: 12-month recall period survey
Number of subjects: 2425
Study 29738183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamiophlomis Rotata Capsule (LRC) at 3 capsules tid for 4 weeks
Number of subjects: 225
Study 29738183 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin hydrochloride sustained-release capsules at 0.2 mg qd for 4 weeks
Number of subjects: 225
Study 29738183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamiophlomis Rotata Capsule (LRC) at 3 capsules tid after 4 weeks of treatment
Number of subjects: 225
Study 29738183 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin hydrochloride sustained-release capsules at 0.2 mg qd after 4 weeks of treatment
Number of subjects: 225
Study 25885780 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally‐made low‐tech rocket stove
Number of subjects: 0
Study 25885780 — intervention group
Group type: EXPERIMENTAL
Intervention: Imported, highly efficient Philips gasifier stove
Number of subjects: 0
Study 25885780 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 24192134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education (group presentations, individual consultations, detailed information)
Number of subjects: 448
Study 24192134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education and environmental dietary modification (restriction of fat, saturated fat, sugar, and salt; increase in fibre, fruit, and vegetables; price discounts for whole fresh fruit; strategic positioning of healthier alternatives; portion size control)
Number of subjects: 448
Study 24192134 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental dietary modification alone
Number of subjects: 448
Study 24192134 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group in Workplace A)
Number of subjects: 448
Study 21441550 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (TNF-α inhibitor)
Number of subjects: 230
Study 21441550 — intervention group
Group type: COMPARATOR
Intervention: Infliximab (TNF-α inhibitor)
Number of subjects: 230
Study 19587779 — intervention group
Group type: EXPERIMENTAL
Intervention: CX3CR1 V249I and T280M polymorphisms
Number of subjects: 368
Study 19587779 — intervention group
Group type: EXPERIMENTAL
Intervention: CX3CL1 levels
Number of subjects: 368
Study 19587779 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype or haplotype frequencies
Number of subjects: 368
Study 17174773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative awakening with conscious analgo-sedation in group A (76 patients)
Number of subjects: 149
Study 17174773 — intervention group
Group type: COMPARATOR
Intervention: Control group B (73 patients)
Number of subjects: 149
Study 15187323 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser treatment with different initial UV doses, treated twice a week for up to 30 sessions.
Number of subjects: 69
Study 15187323 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser treatment for acral and joint areas.
Number of subjects: 69
Study 11502230 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose drink
Number of subjects: 26
Study 11502230 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose drink (informed)
Number of subjects: 26
Study 11502230 — intervention group
Group type: COMPARATOR
Intervention: Aspartame drink (informed)
Number of subjects: 26
Study 11502230 — intervention group
Group type: COMPARATOR
Intervention: Aspartame drink (misinformed)
Number of subjects: 26
Study 11502230 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose drink (misinformed)
Number of subjects: 26
Study 9924240 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled interscalene analgesia (PCIA) with 0.2% ropivacaine
Number of subjects: 60
Study 9924240 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with nicomorphine
Number of subjects: 60
Study 8064736 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acexamate (ZAC) 300 mg
Number of subjects: 276
Study 8064736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 10291784 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncology nurse specialist with continuing education on cancer
Number of subjects: 0
Study 10291784 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing education on cancer alone
Number of subjects: 0
Study 10291784 — intervention group
Group type: COMPARATOR
Intervention: Observation only group
Number of subjects: 0
Study 31706786 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose lurasidone (80mg)
Number of subjects: 42
Study 31706786 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose lurasidone (240mg)
Number of subjects: 42
Study 31170870 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise session (AER)
Number of subjects: 106
Study 31170870 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise session with coordinative demands (AER+C)
Number of subjects: 106
Study 31170870 — intervention group
Group type: COMPARATOR
Intervention: Stretching (Control)
Number of subjects: 106
Study 26918471 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA)
Number of subjects: 52
Study 26918471 — intervention group
Group type: COMPARATOR
Intervention: Titanium
Number of subjects: 52
Study 25692369 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental Durotomy
Number of subjects: 409
Study 25692369 — intervention group
Group type: COMPARATOR
Intervention: No Incidental Durotomy
Number of subjects: 409
Study 23281831 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VibOS
Number of subjects: 10
Study 23281831 — intervention group
Group type: COMPARATOR
Intervention: Inactive VibOS
Number of subjects: 10
Study 21309726 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum UCH-L1 levels
Number of subjects: 59
Study 21309726 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF and serum UCH-L1 levels
Number of subjects: 59
Study 19609280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sodium and potassium intake
Number of subjects: 0
Study 19609280 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotypes of the WNK1 gene
Number of subjects: 0
Study 17268411 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein 18 mg
Number of subjects: 8
Study 17268411 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein 36 mg
Number of subjects: 8
Study 17268411 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenols (gallic acid, caffeic acid, (+)‐catechin, naringenin)
Number of subjects: 8
Study 17268411 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoids (lycopene, beta-carotene, lutein)
Number of subjects: 8
Study 17268411 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-tocopherol
Number of subjects: 8
Study 17268411 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 8
Study 17268411 — intervention group
Group type: EXPERIMENTAL
Intervention: Naringenin
Number of subjects: 8
Study 15301789 — intervention group
Group type: EXPERIMENTAL
Intervention: 1g/day E-EPA supplementation
Number of subjects: 7
Study 11376504 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA (Automated Protamine Dose Assay)
Number of subjects: 50
Study 11376504 — intervention group
Group type: COMPARATOR
Intervention: Empirical protamine ratio (1 mg protamine/100 U heparin)
Number of subjects: 50
Study 11376504 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA and ACT after protamine administration
Number of subjects: 50
Study 11376504 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA
Number of subjects: 50
Study 9130202 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused stimulation intervention focusing on lexical training
Number of subjects: 25
Study 9130202 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study 7945787 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenge with aspirin
Number of subjects: 0
Study 7945787 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenge with sulfites
Number of subjects: 0
Study 7945787 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenge with NSAIDs or food and drug additives
Number of subjects: 0
Study 3370654 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 5778
Study 3370654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5778
Study 31856771 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive Cognitive Therapy (PCT)
Number of subjects: 75
Study 31856771 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (Control)
Number of subjects: 75
Study 28843136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for BED
Number of subjects: 171
Study 25392151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitinol-framed lightweight polypropylene mesh (N-LWM)
Number of subjects: 47
Study 25392151 — intervention group
Group type: COMPARATOR
Intervention: Standard lightweight polypropylene mesh (LWM)
Number of subjects: 47
Study 22703715 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 71
Study 22703715 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboxone
Number of subjects: 71
Study 21057697 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 0.4 microg/kg after administration of protamine (group C)
Number of subjects: 86
Study 21057697 — intervention group
Group type: COMPARATOR
Intervention: No desmopressin (group B)
Number of subjects: 86
Study 21057697 — intervention group
Group type: EXPERIMENTAL
Intervention: No antiplatelet therapy (group A)
Number of subjects: 86
Study 21057697 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 100 mg qd (group B)
Number of subjects: 86
Study 21057697 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 100 mg qd (group C)
Number of subjects: 86
Study 17922971 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pretreatment hemoglobin (Hb) levels (Hb > or = 12)
Number of subjects: 203
Study 17922971 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV(1) > 2 L
Number of subjects: 203
Study 17922971 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pretreatment hemoglobin (Hb) values
Number of subjects: 203
Study 15727952 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (PPARgamma agonist), 5 microM palmitate, chronic treatment for 4 days
Number of subjects: 0
Study 15727952 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (PPARgamma agonist)
Number of subjects: 0
Study 12556642 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 64
Study 12556642 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection alone (TUR)
Number of subjects: 64
Study 9654765 — intervention group
Group type: EXPERIMENTAL
Intervention: Momentary coping assessment via palm-top computer
Number of subjects: 0
Study 9654765 — intervention group
Group type: COMPARATOR
Intervention: Retrospective coping assessment
Number of subjects: 0
Study 7815846 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to Certified Lactation Consultant (CLC) at Hospital H1
Number of subjects: 161
Study 7815846 — intervention group
Group type: COMPARATOR
Intervention: No access to Certified Lactation Consultant (CLC) at Hospital H2
Number of subjects: 161
Study 2632724 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-6 cups of filtered coffee per day
Number of subjects: 107
Study 2632724 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-6 cups of boiled coffee per day
Number of subjects: 107
Study 2632724 — intervention group
Group type: COMPARATOR
Intervention: No coffee for a period of 9 weeks
Number of subjects: 107
Study 4835442 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour fast
Number of subjects: 0
Study 4835442 — intervention group
Group type: COMPARATOR
Intervention: 4-hour fast
Number of subjects: 0
Study 31900172 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days of primaquine (0.5 mg/kg/day)
Number of subjects: 40
Study 31900172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29870820 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Number of subjects: 122
Study 29870820 — intervention group
Group type: COMPARATOR
Intervention: Health education (control)
Number of subjects: 122
Study 27362621 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard preprocedure teaching + additional educational intervention
Number of subjects: 28
Study 27362621 — intervention group
Group type: COMPARATOR
Intervention: Standard preprocedure teaching
Number of subjects: 28
Study 24967454 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 78
Study 24967454 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 78
Study 23488362 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge telephone intervention delivered weekly for the first month and then monthly until the third month (experimental group)
Number of subjects: 40
Study 23488362 — intervention group
Group type: COMPARATOR
Intervention: Usual community care (control group)
Number of subjects: 40
Study 20978195 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cisplatin-based chemotherapy
Number of subjects: 639
Study 20978195 — intervention group
Group type: COMPARATOR
Intervention: Follow-up only (Control)
Number of subjects: 639
Study 18617627 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (EX; n = 36)
Number of subjects: 64
Study 18617627 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of exercise training and weight loss (WLEX; n = 17)
Number of subjects: 64
Study 18617627 — intervention group
Group type: COMPARATOR
Intervention: Weight loss (WL; n = 11)
Number of subjects: 64
Study 18617627 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (EX; n = 36) and Combination (WLEX; n = 17)
Number of subjects: 64
Study 16210715 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid supplementation initiated during the first trimester with 30 mg Fe plus 175 microg folic acid
Number of subjects: 131
Study 16210715 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid supplementation initiated during the first trimester with 60 mg Fe plus 350 microg folic acid
Number of subjects: 131
Study 16210715 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid supplementation initiated at week 20 with 30 mg Fe plus 175 microg folic acid
Number of subjects: 131
Study 16210715 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid supplementation initiated at week 20 with 60 mg Fe plus 350 microg folic acid
Number of subjects: 131
Study 16210715 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 131
Study 12821469 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (3 mg/kg/day intravenously for 14 days) and Doxycycline (200 mg/day orally for 28 days)
Number of subjects: 20
Study 12821469 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 20
Study 12821469 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin and Doxycycline (per-protocol analysis)
Number of subjects: 20
Study 12821469 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls (per-protocol analysis)
Number of subjects: 20
Study 11143912 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy for PLB
Number of subjects: 28
Study 11143912 — intervention group
Group type: COMPARATOR
Intervention: Induction therapy for ESNHL
Number of subjects: 28
Study 11143912 — intervention group
Group type: COMPARATOR
Intervention: Induction therapy for SLB
Number of subjects: 28
Study 11143912 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for PLB
Number of subjects: 28
Study 11143912 — intervention group
Group type: COMPARATOR
Intervention: Overall survival for ESNHL
Number of subjects: 28
Study 11143912 — intervention group
Group type: COMPARATOR
Intervention: Overall survival for SLB
Number of subjects: 28
Study 8841903 — intervention group
Group type: EXPERIMENTAL
Intervention: personal instruction
Number of subjects: 195
Study 8841903 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐education manual
Number of subjects: 195
Study 8841903 — intervention group
Group type: EXPERIMENTAL
Intervention: video
Number of subjects: 195
Study 8841903 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of 2 or more modes
Number of subjects: 195
Study 8841903 — intervention group
Group type: COMPARATOR
Intervention: various modes of oral hygiene education
Number of subjects: 195
Study 1617028 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg methylprednisolone in 10 ml NaCl 0.9% (corticoid group)
Number of subjects: 51
Study 1617028 — intervention group
Group type: COMPARATOR
Intervention: 10 ml NaCl (NaCl group)
Number of subjects: 51
Study 6541715 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ml of essential amino acids
Number of subjects: 43
Study 6541715 — intervention group
Group type: COMPARATOR
Intervention: Normal postoperative electrolyte solutions alone
Number of subjects: 43
Study 30849300 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Care, Saving Lives initiative
Number of subjects: 60
Study 30849300 — intervention group
Group type: COMPARATOR
Intervention: Comparison hospitals (control)
Number of subjects: 60
Study 30212981 — intervention group
Group type: EXPERIMENTAL
Intervention: AML/VAL 5/160 mg FDC
Number of subjects: 238
Study 30212981 — intervention group
Group type: COMPARATOR
Intervention: VAL/HCTZ 160/12.5 mg FDC
Number of subjects: 238
Study 30212981 — intervention group
Group type: COMPARATOR
Intervention: Comparison between AML/VAL and VAL/HCTZ
Number of subjects: 238
Study 26704145 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisture Chamber Spectacles (MCS) worn for 90 min
Number of subjects: 30
Study 26704145 — intervention group
Group type: COMPARATOR
Intervention: Control group received a drop of sterile nonpreserved 0.9% sodium chloride solution
Number of subjects: 30
Study 24251556 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT group)
Number of subjects: 31